Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.47 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.43 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679777 | 0.94 | HDAC1 (0.47) | HDAC1HDAC8PLOD2PLOD3PLOD1 | |
| SCHEMBL14443343 | 0.83 | HDAC1 (0.57) | HDAC1HDAC8PLOD2PLOD3PLOD1 | |
| SCHEMBL19582860 | 0.82 | HDAC1 (0.56) | HDAC1HDAC8PLOD2PLOD3PLOD1 | |
| SCHEMBL4962574 | 0.80 | HDAC1 (0.57) | HDAC1HDAC8PLOD2PLOD3PLOD1 | |
| SCHEMBL3210526 | 0.80 | HDAC1 (0.61) | HDAC1HDAC8PLOD2PLOD3PLOD1 | |
| SCHEMBL454516 | 0.80 | HDAC1 (0.53) | HDAC1HDAC8PLOD2PLOD3PLOD1 | |
| SCHEMBL29367901 | 0.80 | HDAC1 (0.53) | HDAC1HDAC8PLOD2PLOD3PLOD1 | |
| SCHEMBL19958136 | 0.78 | HDAC1 (0.52) | HDAC1HDAC8PLOD2PLOD3PLOD1 | |
| SCHEMBL23265005 | 0.78 | PLOD2 (0.56) | HDAC1HDAC8PLOD2PLOD3PLOD1 | |
| SCHEMBL31686043 | 0.78 | PLOD2 (0.56) | HDAC1HDAC8PLOD2PLOD3PLOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7611715-B2 | Agaricus extract for preventing the induction or metastasis of cancer | SSI CO., LTD. (JP) | 2009-11-03 | — | — | US | claimed |
| US-20070184066-A1 | AGARICUS EXTRACT FOR PREVENTING THE INDUCTION OR METASTASIS OF CANCER | SSI CO., LTD. (JP) | 2007-08-09 | — | — | US | claimed |
| US-20060093618-A1 | Agaricus blazei murill extract capable for preventing cancer induction or metastasis | SSI CO., LTD. (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1535621-A1 | AGARICUS BLAZEI MURILL EXTRACT CAPABLE OF PREVENTING CANCER INDUCTION OR METASTASIS | Kyowa Engineering Co., Ltd. (JP) | 2005-06-01 | — | — | EP | claimed |
| US-20190015484-A1 | NICOTINE-DEGRADING ENZYMES FOR TREATING NICOTINE ADDICTION AND NICOTINE POISONING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-17 | — | — | US | disclosed |
| US-20170022288-A9 | PANCREATIC CANCER ASSOCIATED ANTIGEN, ANTIBODY THERETO, AND DIAGNOSTIC AND TREATMENT METHODS | MICHL JOSEF (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2016167605-A2 | METHOD FOR INHIBITING LUNG CANCER OF SMOKERS AND NON-SMOKERS USING HYPERTENSION MEDICINE | 서울대학교 산학협력단 | 2016-10-20 | — | — | WO | disclosed |
| US-20160083475-A1 | PANCREATIC CANCER ASSOCIATED ANTIGEN, ANTIBODY THERETO, AND DIAGNOSTIC AND TREATMENT METHODS | MICHL JOSEF (US) | 2016-03-24 | — | — | US | disclosed |
| US-8969544-B2 | Combined use of PRAME inhibitors and HDAC inhibitors | BERNARDS RENé (NL) | 2015-03-03 | — | — | US | disclosed |
| EP-1711210-B1 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2013-12-11 | — | — | EP | disclosed |
| US-20130123327-A1 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | BERNARDS RENE (NL) | 2013-05-16 | — | — | US | disclosed |
| US-7928081-B2 | biodrugs contains siRNA or vector encoding siRNA, including a retinoid as antitumor agents, anticarcinogenic agents | Bernards, Rene (NL) | 2011-04-19 | — | — | US | disclosed |
| US-7611715-B2 | Agaricus extract for preventing the induction or metastasis of cancer | SSI CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20080119424-A1 | Combined Use of Prame Inhibitors and Hdac Inhibitors | BERNARDS RENE | 2008-05-22 | — | — | US | disclosed |
| US-20070184066-A1 | AGARICUS EXTRACT FOR PREVENTING THE INDUCTION OR METASTASIS OF CANCER | SSI CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060258841-A1 | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2006-11-16 | — | — | US | disclosed |
| US-20060093618-A1 | Agaricus blazei murill extract capable for preventing cancer induction or metastasis | SSI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1761482-A | The antigen relevant with cancer of pancreas, at its antibody and diagnosis and Therapeutic Method | UNIV NEW YORK (US) | 2006-04-19 | — | — | CN | disclosed |
| EP-1535621-A1 | AGARICUS BLAZEI MURILL EXTRACT CAPABLE OF PREVENTING CANCER INDUCTION OR METASTASIS | Kyowa Engineering Co., Ltd. (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123327-A1 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | HDAC5, HDAC8, HDAC11 | HDAC1 7/4885HDAC8 2/4885PLOD2 4025/4885 |
| US-20190015484-A1 | NICOTINE-DEGRADING ENZYMES FOR TREATING NICOTINE ADDICTION AND NICOTINE POISONING | ENGASE, NAPRT, ACHE | HDAC1 139/4885HDAC8 830/4885PLOD2 1769/4885 |
| US-20170022288-A9 | PANCREATIC CANCER ASSOCIATED ANTIGEN, ANTIBODY THERETO, AND DIAGNOSTIC AND TREATMENT METHODS | RNASE1, AMY2A, PA2G4 | HDAC1 3772/4885HDAC8 3382/4885PLOD2 1886/4885 |
| US-20080119424-A1 | Combined Use of Prame Inhibitors and Hdac Inhibitors | HDAC5, HDAC8, HDAC11 | HDAC1 7/4885HDAC8 2/4885PLOD2 4025/4885 |
| US-20160083475-A1 | PANCREATIC CANCER ASSOCIATED ANTIGEN, ANTIBODY THERETO, AND DIAGNOSTIC AND TREATMENT METHODS | RNASE1, AMY2A, PA2G4 | HDAC1 3772/4885HDAC8 3382/4885PLOD2 1886/4885 |
| US-20060258841-A1 | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods | RNASE1, AMY2A, PA2G4 | HDAC1 3772/4885HDAC8 3382/4885PLOD2 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.